CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. today announced that the company's President and Chief Executive Officer, Chip Clark, will provide an overview of the company’s technologies and programs at the Biotech Showcase 2012 Conference (San Francisco, CA, January 9-11; presentation on Tuesday, January 10, at 11:30 a.m. PT).
About Genocea
Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Pneumococcus, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide.
About the Biotech Showcase™ (Innovation – Opportunity – Collaboration):
Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all showcase participants can schedule one-on-one meetings through the organizer’s online system, partneringONE®. Public and private investors are always invited to attend the showcase on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life sciences industry. Visit our website for more information: www.ebdgroup.com/bts.